ReviewFrontiers in oral health2026
Periodontal management in patients with diabetes: the impact of periodontal treatment on cardiometabolic biomarkers.
Review in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Type II Diabetes Mellitus (T2DM) and periodontitis present an independent bidirectional relationship. While T2DM is associated with a higher prevalence, incidence, and severity of periodontitis, periodontitis might worsen glycemic control and inflammatory biomarker levels in diabetics. Although there is no standardized therapy for the treatment of diabetic patients with periodontitis, different periodontal interventions report improvements in clinical and cardiometabolic parameters. Objective: To summarize the current evidence regarding the clinical management of patients with T2DM and periodontitis, with a secondary focus on the impact of periodontal interventions on cardiometabolic biomarkers. Materials and methods: A literature search was conducted between 2010 and 2026. Information about the clinical management of periodontitis in individuals with T2DM and its impact on cardiometabolic biomarkers was classified and summarized. Results: A comprehensive periodontal examination and diagnosis should be performed, with close collaboration with the patient's physician. Prior dental treatment, capillary blood glucose between 70 and 180 mg/dL, and up to 240 mg/dL in emergency procedures are suggested. The EFP's stepwise treatment approach is recommended, considering periodontal therapy in multiple sessions. Antibiotic therapy or prophylaxis are not recommended in all cases, whereas periodontal maintenance may be required every 3-6 months. Periodontal interventions in diabetic individuals have been shown to decrease glycated hemoglobin (HbA1c) and C-reactive protein (CRP), together with other inflammatory and cardiometabolic biomarkers. Conclusions: Patients with T2DM benefit from several periodontal treatment strategies, with a positive impact on inflammatory and cardiometabolic biomarkers associated with eventual reductions in diabetic control and systemic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.